Clinical Trials · NCT06339086
Efficacy and Safety of Semaglutide Injection in Subjects With Type 2 Diabetes
- Phase
- Phase 3
- Recruitment status
- Unknown
- Sponsor
- Chengdu Brilliant Pharmaceutical Co., Ltd.
- Enrollment
- 478
- Start date
- Apr 2024
- Locations
- See registry
- Primary endpoint
- Change in HbA1c